Optimal glucocorticoid tapering in anti-synthetase syndrome–associated interstitial lung disease: A multicentre MYKO cohort study
Modern Rheumatology · 04.11.2026 · 36 (6) · 1007-1015
DOI: 10.1093/mr/roag044 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, online erschienen am 17.05.2026. Verfasst von Hirofumi Miyake und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Tenri Hospital, Tenri, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Glucocorticoids, Myositis, Prednisolone. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Institutional Review Board of Tenri Hospital.
Abstract (Originalsprache)
Objectives
To explore glucocorticoid tapering targets in patients with acute/subacute anti-synthetase syndrome–associated interstitial lung disease (ASyS-ILD).
Methods
We retrospectively analysed 86 patients with newly diagnosed acute/subacute ASyS-ILD from the MYKO cohort. Patients were grouped using prednisolone-equivalent dose thresholds of 15, 12.5, and 10 mg/day at 6 months. Exploratory three-group analyses categorised patients into ≤ 12.5, 12.5–15, and >15 mg/day. Matching weights adjusted for baseline confounders. Cox proportional-hazards models evaluated 5-year all-cause mortality and event-free survival for disease flares and infections requiring hospitalisation. A multivariable logistic regression assessed factors associated with achieving ≤ 15 mg/day at 6 months.
Results
In two-group analyses, the ≤ 15 mg/day group had a lower infection risk (hazard ratio 0.18, 95% confidence interval 0.04–0.81), whereas analyses using other thresholds showed no clear differences. In the three-group analyses, patients receiving 12.5–15 mg/day tended to have the lowest flare risk. Female sex was associated with achieving ≤ 15 mg/day at 6 months (odds ratio 3.29, 95% confidence interval 1.09–10.13).
Conclusions
Tapering to a prednisolone-equivalent dose of 12.5–15 mg/day at 6 months may represent a reasonable target to balance risks of flares and infections in patients with acute/subacute ASyS-ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Internal Medicine, Tenri Hospital, Tenri, Japan.
- Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Hirofumi Miyake, Takuya Kotani, Shogo Matsuda, Takashi Kida, Junya Kitai, Yoichi Nakayama, Tsuneo Sasai, Hideaki Tsuji, Ran Nakashima
Förderung
- Institutional Review Board of Tenri Hospital
Zitieren
APA
Miyake, H., Kotani, T., Suzuka, T., Matsuda, S., Oe, K., Yamamoto, M., Akiyama, C., Seno, T., Kida, T., Sagawa, T., Inoue, H., Kitai, J., Shimada, Y., Hirobe, K., Yoshida, K., Ogawa, A., Nakakubo, Y., Nakayama, Y., Nohda, Y., …, & Nakashima, R. (2026). Optimal glucocorticoid tapering in anti-synthetase syndrome–associated interstitial lung disease: A multicentre MYKO cohort study. Modern Rheumatology, 36(6), 1007-1015. https://doi.org/10.1093/mr/roag044
Vancouver
Miyake H, Kotani T, Suzuka T, Matsuda S, Oe K, Yamamoto M, et al. Optimal glucocorticoid tapering in anti-synthetase syndrome–associated interstitial lung disease: A multicentre MYKO cohort study. Modern Rheumatology. 2026;36(6):1007-1015. doi:10.1093/mr/roag044
BibTeX
@article{Miyake2026,
author = {Miyake, Hirofumi and Kotani, Takuya and Suzuka, Takayasu and Matsuda, Shogo and Oe, Katsumasa and Yamamoto, Mahiro and Akiyama, Chifumi and Seno, Takahiro and Kida, Takashi and Sagawa, Tomoya and Inoue, Hironori and Kitai, Junya and Shimada, Yuki and Hirobe, Keisuke and Yoshida, Kazuma and Ogawa, Atsubumi and Nakakubo, Yuto and Nakayama, Yoichi and Nohda, Yasuhiro and Sasai, Tsuneo and Tsuji, Hideaki and Nakashima, Ran},
title = {Optimal glucocorticoid tapering in anti-synthetase syndrome–associated interstitial lung disease: A multicentre MYKO cohort study},
journal = {Modern Rheumatology},
year = {2026},
volume = {36},
number = {6},
pages = {1007--1015},
doi = {10.1093/mr/roag044}
}
EUVIMED